Clinical Trials
2 trialsNCT04330625 2022-11-08
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Duke University
Phase 1 Terminated
NCT04253223 2021-06-11
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
Duke University
Phase 1 Terminated